Abstract:Background: Triple-negative breast cancer (TNBC) is the most heterogenous and aggressive subtype of breast cancer. Chemotherapy remains the standard treatment option for patients with TNBC owing to the unavailability of acceptable targets and biomarkers in clinical practice. Novel biomarkers and targets for patient stratification and treatment of TNBC are urgently needed. It has been reported that the overexpression of DNA damage-inducible transcript 4 gene (DDIT4) is associated with resistance to neoadjuvant chemotherapy and poor prognosis in patients with TNBC. In this study, we aimed to identify novel biomarkers and therapeutic targets using RNA sequencing (RNA-seq) and data mining using data from public databases. Methods: RNA sequencing (RNA-Seq) was performed to detect the different gene expression patterns in the human TNBC cell line HS578T treated with docetaxel or doxorubicin. Sequencing data were further analyzed by the R package "edgeR" and "clusterProfiler" to identify the profile of differentially expressed genes (DEGs) and annotate gene functions. The prognostic and predictive value of DDIT4 expression in patients with TNBC was further validated by published online data resources, including TIMER, UALCAN, Kaplan-Meier plotter, and LinkedOmics, and GeneMANIA and GSCALite were used to investigate the functional networks and hub genes related to DDIT4, respectively. Results: Through the integrative analyses of RNA-Seq data and public datasets, we observed the overexpression of DDIT4 in TNBC tissues and found that patients with DDIT4 overexpression showed poor survival outcomes. Notably, immune infiltration analysis showed that the levels of DDIT4 expression correlated negatively with the abundance of tumor-infiltrating immune cells and immune biomarker expression, but correlated positively with immune checkpoint molecules. Furthermore, DDIT4 and its hub genes (ADM, ENO1, PLOD1, and CEBPB) involved in the activation of apoptosis, cell cycle, and EMT pathways. Eventually, we found ADM, ENO1, PLOD1, and CEBPB showed poor overall survival in BC patients. Conclusion: In this study, we found that DDIT4 expression is associated with the progression, therapeutic efficacy, and immune microenvironment of patients with TNBC, and DDIT4 would be as a potential prognostic biomarker and therapeutic target. These findings will help to identify potential molecular targets and improve therapeutic strategies against TNBC.

DNAJB4 Promotes Triple-Negative Breast Cancer Cell Apoptosis Via Activation of the Hippo Signaling Pathway

DNAJB4 Suppresses Breast Cancer Progression and Promotes Tumor Immunity by Regulating the Hippo Signaling Pathway

Knockdown of B7H6 Inhibits Tumor Progression in Triple-Negative Breast Cancer.

HMGN4 Plays a Key Role in STAT3-mediated Oncogenesis of Triple-Negative Breast Cancer.

Regulation of DNA-PK activity promotes the progression of TNBC via enhancing the immunosuppressive function of myeloid-derived suppressor cells

BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways

Regulation of Hippo Signaling and Triple Negative Breast Cancer Progression by an Ubiquitin Ligase RNF187

Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer

Naphthoquinone-derived ZSW-4B induces apoptosis in triple-negative breast cancer via AMPK signalling activation

Inhibition of endoplasmic reticulum stress alleviates triple-negative breast cancer cell viability, migration, and invasion by Syntenin/SOX4/Wnt/β-catenin pathway via regulation of heat shock protein A4

4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells

DNAJA1 promotes proliferation and metastasis of breast cancer by activating mutant P53/NF-κB pathway

ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer

PBX3-activated DLG1-AS1 Can Promote the Proliferation, Invasion and Migration of TNBC Cells by Sponging Mir-16-5p

The homeoprotein HOXB2 limits triple-negative breast carcinogenesis via extracellular matrix remodeling

Integrated Analysis of Expression Profiling Data Identifies Three Genes in Correlation with Poor Prognosis of Triple-Negative Breast Cancer

DAXX, As a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.

HNRNPU Promotes the Progression of Triple-Negative Breast Cancer Via RNA Transcription and Alternative Splicing Mechanisms.

ZNF703 promotes triple-negative breast cancer cells through cell-cycle signaling and associated with poor prognosis

HDAC7 inhibits cell proliferation via NudCD1/GGH axis in triple-negative breast cancer

ALX4, an Epigenetically Down Regulated Tumor Suppressor, Inhibits Breast Cancer Progression by Interfering Wnt/β-catenin Pathway